---
figid: PMC6262052__fnsyn-10-00042-g0004
figlink: /pmc/articles/PMC6262052/figure/F4/
number: Figure 4
caption: A scheme to explain how CP-AMPARs may trigger LTP2. (A) Baseline conditions.
  The synaptic complement comprises NMDARs (predominantly GluN1/GluN2A/GluN2B) and
  calcium impermeable (CI)-AMPARs (note only one of each receptor type is shown for
  simplicity). (B,C) The first TBS (or cTBS, cHFS, etc.) induces LTP1 via activation
  of CaMKII and involves the synaptic insertion of additional CI-AMPARs. (D) The first
  TBS also drives CP-AMPARs into the perisynaptic plasma membrane, via a pathway involving
  protein kinase A (PKA). (E) Additional TBS activates NMDARs to drive CP-AMPARs from
  the perisynaptic to the synaptic membrane. (F) Baseline stimulation leads to Ca2+
  entry via CP-AMPARs, which triggers de novo protein synthesis (via PI3K and MAPK).
  (G) Consequently, what follows is spine growth and the incorporation of additional
  CI-AMPARs. CP-AMPARs are removed from the synapse around the same time.
pmcid: PMC6262052
papertitle: The Role of Calcium-Permeable AMPARs in Long-Term Potentiation at Principal
  Neurons in the Rodent Hippocampus.
reftext: Pojeong Park, et al. Front Synaptic Neurosci. 2018;10:42.
pmc_ranked_result_index: '125028'
pathway_score: 0.8878071
filename: fnsyn-10-00042-g0004.jpg
figtitle: Scheme to explain how CP-AMPARs may trigger LTP2
year: '2018'
organisms: Homo sapiens
ndex: 03b7022a-de95-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6262052__fnsyn-10-00042-g0004.html
  '@type': Dataset
  description: A scheme to explain how CP-AMPARs may trigger LTP2. (A) Baseline conditions.
    The synaptic complement comprises NMDARs (predominantly GluN1/GluN2A/GluN2B) and
    calcium impermeable (CI)-AMPARs (note only one of each receptor type is shown
    for simplicity). (B,C) The first TBS (or cTBS, cHFS, etc.) induces LTP1 via activation
    of CaMKII and involves the synaptic insertion of additional CI-AMPARs. (D) The
    first TBS also drives CP-AMPARs into the perisynaptic plasma membrane, via a pathway
    involving protein kinase A (PKA). (E) Additional TBS activates NMDARs to drive
    CP-AMPARs from the perisynaptic to the synaptic membrane. (F) Baseline stimulation
    leads to Ca2+ entry via CP-AMPARs, which triggers de novo protein synthesis (via
    PI3K and MAPK). (G) Consequently, what follows is spine growth and the incorporation
    of additional CI-AMPARs. CP-AMPARs are removed from the synapse around the same
    time.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PRKAR2B
  - MAPK12
  - GRIN2B
  - MAPK8
  - MAPK11
  - GRIN2A
  - MAPK3
  - MAPK10
  - MAPK13
  - MAPK1
  - CAMK2B
  - MAPK14
  - GRIN2C
  - PRKAR2A
  - PRKACA
  - MAPK9
  - GRIN3A
  - PRKAR1B
  - GRIN3B
  - PRKACG
  - PRKAR1A
  - GRIN1
  - GRIN2D
  - PRKACB
  - Ca
genes:
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2B
  entrez: '5577'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: NMDAR
  symbol: NMDAR
  source: bioentities_symbol
  hgnc_symbol: GRIN2B
  entrez: '2904'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: NMDAR
  symbol: NMDAR
  source: bioentities_symbol
  hgnc_symbol: GRIN2A
  entrez: '2903'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: CaMKII
  symbol: CAMK2
  source: hgnc_alias_symbol
  hgnc_symbol: CAMK2B
  entrez: '816'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: NMDAR
  symbol: NMDAR
  source: bioentities_symbol
  hgnc_symbol: GRIN2C
  entrez: '2905'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2A
  entrez: '5576'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACA
  entrez: '5566'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: NMDAR
  symbol: NMDAR
  source: bioentities_symbol
  hgnc_symbol: GRIN3A
  entrez: '116443'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1B
  entrez: '5575'
- word: NMDAR
  symbol: NMDAR
  source: bioentities_symbol
  hgnc_symbol: GRIN3B
  entrez: '116444'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACG
  entrez: '5568'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1A
  entrez: '5573'
- word: NMDAR
  symbol: NMDAR
  source: bioentities_symbol
  hgnc_symbol: GRIN1
  entrez: '2902'
- word: NMDAR
  symbol: NMDAR
  source: bioentities_symbol
  hgnc_symbol: GRIN2D
  entrez: '2906'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACB
  entrez: '5567'
chemicals:
- word: Ca
  source: MESH
  identifier: D002118
diseases: []
---
